Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoViricides, Inc. on June 6, 2019. The report discloses corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- Appointment: Mark Day, Ph.D., was appointed as a new Independent Member of the Board of Directors effective June 6, 2019.
- Committee Assignments: Dr. Day will serve on the Audit, Compensation, and Nominating Committees.
- Qualifications: Dr. Day brings approximately 20 years of experience in R&D and business development within the biotech industry, including prior executive roles at Bioasis Technologies, Alexion Pharmaceuticals, and Bristol-Myers Squibb.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document confirms there are no undisclosed transactions or arrangements regarding Dr. Day's selection requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the independence status of Mark Day, Ph.D., under NYSE American Rule 803A.
- Review the attached Director Retainer Agreement (Exhibit 10.1) for compensation details.
- Confirm the composition of the Audit, Compensation, and Nominating Committees following this appointment.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.